Estimated Effectiveness of COVID-19 Messenger RNA Vaccination Against SARS-CoV-2 Infection Among Older Male Veterans Health Administration Enrollees, January to September 2021

Yinong Young-Xu; Gabrielle M Zwain; Ethan I Powell; Jeremy Smith

doi:10.1001/jamanetworkopen.2021.38975

Estimated Effectiveness of COVID-19 Messenger RNA Vaccination Against SARS-CoV-2 Infection Among Older Male Veterans Health Administration Enrollees, January to September 2021

JAMA Netw Open. 2021 Dec 1;4(12):e2138975. doi: 10.1001/jamanetworkopen.2021.38975.

Authors

Yinong Young-Xu^{1

2}, Gabrielle M Zwain¹, Ethan I Powell¹, Jeremy Smith¹

Affiliations

¹ White River Junction Veterans Affairs Medical Center, White River Junction, Vermont.
² Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire.

Abstract

This case-control study examines estimated COVID-19 messenger RNA vaccination effectiveness against SARS-CoV-2 infection from January to September 2021 among fully vaccinated male veterans aged 65 years or older.

Publication types

Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

2019-nCoV Vaccine mRNA-1273
Aged
Aged, 80 and over
BNT162 Vaccine
COVID-19 / prevention & control*
COVID-19 / virology
COVID-19 Vaccines*
Humans
Male
RNA, Messenger*
SARS-CoV-2
Treatment Outcome
United States
United States Department of Veterans Affairs
Vaccination*
Veterans Health Services
Veterans Health*
Veterans*

Substances

COVID-19 Vaccines
RNA, Messenger
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine

Supplementary concepts

SARS-CoV-2 variants